In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells
Open Access
- 14 May 2002
- Vol. 94 (10), 2653-2662
- https://doi.org/10.1002/cncr.10543
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Long-Term Survival and Late Deaths after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1999
- Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces ApoptosisBlood Cells, Molecules, and Diseases, 1997
- Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 1997
- Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid LeukemiaNew England Journal of Medicine, 1994
- Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.Journal of Clinical Investigation, 1993
- Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabineAmerican Journal of Hematology, 1993
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990
- Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemiaCancer, 1987
- An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activityCell, 1984
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973